Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + ibrutinib + CHOP-21 for untreated young high-risk diffuse large B-cell lymphoma
2015-005273-20Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab, ibrutinib, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Progression-free survival and 2-year progression-free survival. Started May 2021; status: terminated.
02
Drugs
obinutuzumabibrutinibcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-005273-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005273-20.